J.P. Morgan analyst Anupam Rama has maintained their bullish stance on TVTX stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anupam Rama has given his Buy rating due to a combination of factors that highlight Travere Therapeutics’ promising outlook. The company recently reported a strong third quarter for its product Filspari, which is primarily driven by robust demand in the IgAN market. This demand is expected to continue as the company efficiently manages patient conversion and time to fill prescriptions.
Additionally, the upcoming FSGS PDUFA date is anticipated to be a positive catalyst for the stock, with expectations of a smooth approval process. If approved, this could enhance Travere’s strategic profile significantly. Moreover, despite some seasonal fluctuations, the company has seen a strong trend in patient start forms, indicating sustained interest and potential growth. These factors collectively justify the Buy rating as Travere is positioned for long-term potential.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $47.00 price target.